Ono Pharmaceutical
Aug 03, 2020
Enough Of Wasting Away From Cancer: Companies Gear Up To Tackle Cachexia
The dynamics of the cancer cachexia market is expected to gain momentum as several companies are testing the waters, advancing cancer cachexia pipeline. More than half of the cancer patients suffer from cachexia, and over 30% of the cancer patients succumb to death due to complications that arise from cachexi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
